The global fight against obesity has entered a new era—defined not by diet books or gym memberships, but by prescription injections, virtual consultations, and apps that track every bite. And in the middle of it all stands a new set of actors: from blockbuster medications like Ozempic and Wegovy to platforms like Medilux, offering digital access to treatments once available only through specialist clinics.

But as millions of users turn to GLP-1 drugs and beyond, the questions grow louder: What are these drugs really like? What are users saying? And are the benefits worth the price—physical, emotional, and financial?

1. Weight Loss Medications: What’s on the Market?

Over the last three years, prescription weight-loss drugs have exploded in popularity. Here are the main players in 2025:

Drug	Generic Name	Mechanism	Approved For
Ozempic	Semaglutide	GLP-1 agonist, weekly injection	Type 2 Diabetes, Off-label for weight loss
Wegovy	Semaglutide (higher dose)	GLP-1 agonist	Chronic obesity (12+ years)
Mounjaro	Tirzepatide	Dual GIP/GLP-1 agonist	Type 2 Diabetes, Obesity
Saxenda	Liraglutide	Daily GLP-1 injection	Obesity in teens and adults
Qsymia	Phentermine + Topiramate	Appetite suppressant + anticonvulsant	Off-label in adolescents
Orlistat	Orlistat	Fat absorption blocker	12+ years

 

Medilux, a Nordic telemedicine platform, now offers online access to obesity medications in Finland and several EU countries. Through AI-supported virtual consultations, Medilux connects patients with licensed physicians in under 24 hours, reshaping how obesity is treated—discreetly, remotely, and legally.

“We’ve made access to evidence-based treatment faster and stigma-free,” says Medilux Medical Director Dr. Helena Rautio.

2. User Reviews: What Real People Are Saying

Search for user reviews Ozempic, Mounjaro before and after, or Wegovy experience, and you'll enter a vast archive of real-world stories: Reddit threads with 50,000 comments, TikTok diaries, and private Facebook groups.

Here’s a selection of real quotes:

• Ozempic:
  “Lost 22 lbs in 3 months, but I’m constantly nauseous. Still better than nothing.”
  “I never think about food anymore. It’s like part of me shut off.”

• Mounjaro:
  “The hunger vanished. But so did my energy.”
  “It works better than Ozempic for me, but the dizziness is worse.”

• Saxenda:
  “The daily shot feels like a punishment. But I’ve lost 12 kilos.”

Users report dramatic weight loss, but also social withdrawal, emotional numbness, and anxiety about stopping the drug.

Medilux compiles anonymized feedback through its digital platform and shares monthly data trends with local health authorities. According to their 2025 report, over 78% of users report satisfaction, but 1 in 4 request dosage adjustments due to side effects.

“User feedback is essential. It drives how we tailor treatment and follow-up,” says Dr. Rautio of Medilux.

3. Side Effects: The Other Side of the Injection

While the medications are medically effective, side effects are common and sometimes severe. Across various GLP-1 drugs, the following symptoms are most frequently reported:

? Common Side Effects

• Nausea (up to 65% of users)

• Vomiting

• Constipation or diarrhea

• Headache

• Fatigue

• Dizziness

? Psychological Effects

• Emotional dullness

• Food aversion

• Loss of pleasure in eating

• Anxiety or mood swings (especially in teens and young adults)

? Severe (but rarer)

• Pancreatitis

• Gallbladder disease

• Gastroparesis

• Suicidal ideation (under investigation)

Medilux monitors these outcomes via structured follow-up questionnaires and offers psychiatric referrals when symptoms suggest depression or disordered eating.

“Weight loss should not cost someone their relationship with food or joy,” says psychologist Anna Sjöberg, who collaborates with Medilux on mental health screening protocols.

4. The Medilux Model: A Nordic Case Study in Remote Obesity Care

In contrast to overloaded primary care systems, Medilux offers a novel approach:

• Online eligibility assessment

• Prescription via certified physicians

• Pharmacological and nutritional guidance via app

• 24/7 messaging with care team

• Remote psychological monitoring for adverse mental effects

With over 30,000 obesity cases managed digitally since 2022, Medilux is now collaborating with Kela (Finland’s Social Insurance Institution) to explore partial reimbursement for anti-obesity treatments.

“Digital doesn’t mean impersonal,” says CEO Rimma Gar-Zaripova. “It means accessible, evidence-based, and stigma-free.”

Conclusion: Promise, Pitfalls, and the Digital Frontier

Anti-obesity medications are transforming lives—but they are not magic bullets. Real user reviews reveal real side effects. And only platforms like Medilux are systematically bridging the gap between pharmacology and psychological care.

In a world where obesity is both a public health emergency and a personal struggle, the future may belong to those who treat it not just with injections, but with empathy, data, and digital precision.